Alumis Inc. has reported a stock sale by its Chief Financial Officer, John R. Schroer. The transaction involved the sale of 794 shares at an average price of $6.52. This sale is significant as it is tied to tax obligations resulting from the vesting of restricted stock units.

The sale took place on November 2, 2026, and was officially filed with the SEC on November 4, 2026. This move highlights how executives within the pharmaceutical preparations industry manage their equity holdings, particularly in light of tax implications.

Background

Alumis Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol ALMS. Recently, it has been actively filing various forms with the SEC, including multiple Form 4 filings on the same day as this transaction.

What the Filing Says

The SEC filing indicates that the shares sold by Schroer were part of a required sell-to-cover transaction to meet tax obligations incurred from the vesting and settlement of restricted stock units. The filing notes, "The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025."

Impact

This transaction may affect shareholders and other stakeholders in Alumis Inc., as it reflects the company's approach to managing executive compensation and tax liabilities. The pharmaceutical industry, in general, may see similar actions from executives as companies navigate equity management and tax obligations.

What's Next

The filing does not say what happens next.